Stocks / NASDAQ / Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc.

Our Opinion

Conatus Pharmaceuticals Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

The company announced in the following press release that, “Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models.” Read the full article.

Company Description

Conatus Pharmaceuticals, Inc. is a biotechnology company engages in the development and commercialization of medicines to liver diseases treatment. It focuses in development of Emricasan, orally active protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death or apoptosis for the interruption of progress of liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in Dan Diego, CA. [Source: MarketWatch]

Company Website: